Oral Manifestations of Systemic Sclerosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

85 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-06-30

Study Completion Date

2021-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Systemic sclerosis (SSc) is a rare multisystem connective-tissue disorder characterized by three major pathological hallmarks: widespread fibrosis, vasculopathy and immunological abnormalities. As all connective tissues can be affected, this condition has multiple effects on the orofacial region. Indeed, the latter is involved in approximately 80% of SSc patients. Oral manifestations have a major impact on quality of life and require specific treatments that should be performed as early as possible.

Widening of the periodontal ligament space, that seems to be linked to an increased collagen synthesis, is one of the most common dental radiographic finding. However, this radiologic sign has been mostly studied on two-dimensional radiographs. The investigators have recently described in a patient suffering from SSc the existence of calcifications within the periodontal ligament space using Cone Beam Computed Tomography (CBCT) approach (Jung et al., Oral Surg Oral Med Oral Pathol Oral Radiol 2013). Such calcifications, that have never been observed before, could be part of the phenotypic spectrum of the disease, in particular when dystrophic calcinosis is associated. They could furthermore constitute a specific feature of SSc. However, this radiographic sign requires to be investigated in a largest number of patients.

Several cytokines have been implicated in SSc pathogenesis. A recent study has revealed that elevated CXCL4 serum levels correlate with disease complications, suggesting that this molecule could be used as a prognostic biomarker. Increased IL-6 serum levels also correlate with SSc severity. Gingival crevicular fluid can be easily collected from the gingival crevice surrounding the teeth and constitute an indicator of local but also systemic inflammation. Analysis of gingival crevicular fluid cytokine profile could contribute to the identification of specific SSc biomarkers and allow a better comprehension of oral manifestations pathogenesis.

The aim of this case-control study is to characterize precisely the oral manifestations associated with SSc within the National Referral Center for Rare Autoimmune Diseases (Strasbourg, France) patient cohort in order to identify specific radiological, clinical and/or biological signs. Some of them could be correlated to the severity or to the prognosis of the disease. To the investigators knowledge it is the first study using tridimensional CBCT approach.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Optical Coherence Tomography Imaging in Systemic Sclerosis

NCT04532151

Systemic Sclerosis Early Systemic Sclerosis Without Clinical Scleroderma and Onset < 2 Years

COMPLETED NA

Oral Health and People With Systemic Sclerosis

NCT01817361

Systemic Sclerosis

COMPLETED

NVC Test in Order to Assess Pathological Changes in Family Members of Patient Diagnosed With SSc

NCT02795221

According to the IRB Approval

UNKNOWN

Evaluation of the Serum Soluble Fractalkine as a Biomarker of Pulmonary Fibrosis in Systemic Sclerosis

NCT03508375

Systemic Scleroderma

UNKNOWN NA

Echo Systemic Sclerosis

NCT03143413

Systemic Sclerosis Gougerot Sjogren Syndrome Sicca-Asthenia-Polyalgia Syndrome

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Scleroderma, Systemic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Measurement of the periodontal ligament space

Evaluation of the width of the ligament in patients with SSc and comparison to the width found in control.

Group Type OTHER

Cone Beam Computed Tomography (CBCT)

Intervention Type RADIATION

Radiographic analysis of oro-facial manifestations

Establishment of a complete clinical phenotypic description of oral manifestations associated with SSc and comparison with the control group.

Group Type OTHER

Cone Beam Computed Tomography (CBCT)

Intervention Type RADIATION

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cone Beam Computed Tomography (CBCT)

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males and females ≥ 18 years (18th birthday completed)
* Affiliation to a social security scheme
* Signed informed consent form prior to inclusion in the study
* More than 12 natural teeth suitable for evaluation

* Subjet that underwent or must undergo an upper and a lower jaw bone Cone Beam Computed Tomography examination (impacted teeth assessment, implant treatment planning)

Exclusion Criteria

* Overt acute or chronic infection (HIV, viral hepatitis…) known at the time of the oral examination
* Progressive neoplasia or neoplasia diagnosed within 2 years prior to the study
* Ongoing antibiotic treatment or within 3 months before oral examination
* Individuals at risk of infective endocarditis
* Oral antiseptics within the week before oral examination (chlorhexidine mouthwashes…)
* Periodontal specialized treatments, root scaling/root planning or periodontal surgical treatment within the year before oral examination
* Ongoing medical treatment inducing a significant modification of the gingival state (anti-epileptic drugs…)
* Smoking (≥ 10 cigarettes per day)
* Pregnancy female subjects (positive urine pregnancy test)
* Lactating female subjects
* Impossibility to provide accurate informations (emergency situation, comprehension difficulties…)

* Patient currently involved in an other clinical trial (drug) or in an exclusion period following participation in another clinical trial
* Other associated systemic auto-immune disease (Sjögren syndrome with positive serum anti-SSA and/or anti-SSB auto-antibodies, systemic lupus erythematosus…)
* Progressive chronic illness other than systemic sclerosis (diabetes…)
* Immunosuppressive therapy during the last month
* Corticosteroid ≥10 mg/day during the last month
* Hematopoietic stem cell transplant recipient
* Another cause of skin sclerosis (radiotherapy on the oro-facial region…)

* Systemic chronic or evolutive illness at the time of the inclusion
* Progressive pathology involving the maxilla or the mandible at the time of the inclusion (tumor…)
* Ongoing treatment with corticsteroids or non-steroidal anti-inflammatory drugs

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes